GENERAL28 Sept 2026
Sun Pharma bags rights to $3.7 billion cholesterol drug market globally
Sun Pharma has bagged the rights to sell and make LIB Therapeutics' once-monthly cholesterol drug in markets outside the US and China. This follows the drug's approval in the European Union. The deal opens up a slice of the global cholesterol drug market, which the report values at $3.7 billion. If you hold Sun Pharma shares, keep an eye on company updates before acting.
Key Statutory Highlights
- Sun Pharma will commercialise and manufacture LIB Therapeutics' once-monthly cholesterol drug.
- The rights cover markets outside the US and China.
- The deal follows the drug's approval in the European Union.
Actionable Advice for Taxpayers / Founders:If you are a Sun Pharma shareholder, treat this as one development among many and wait for the company's own disclosures before you take any investment decision.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: